Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted Psychotherapy for Severe PTSD (Canada)
NCT03485287Phase 2Completed
- Sponsor
- Lykos Therapeutics
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Lykos Therapeutics. Started Mar 2018; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03485287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485287.